Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q/C TECHNOLOGIES, INC. Director's Dealing 2019

Jan 2, 2019

35313_dirs_2019-01-02_1c68911a-ef49-4a47-b081-607117a9ba93.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akers Biosciences, Inc. (AKER)
CIK: 0001321834
Period of Report: 2018-12-28

Reporting Person: Yeaton Howard (CEO, CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-12-28 Common Stock A 7500 $1.27 Acquired 7500 Direct